Pancreatic Adenocarcinoma Market

• The Pancreatic Adenocarcinoma Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• The leading Pancreatic Adenocarcinoma companies such as Panbela Therapeutics, Lokon Pharma, Candel Therapeutics, Oncolytics Biotech, Theriva Biologics and others are developing therapies for Pancreatic Adenocarcinoma treatment.
• The main objective of the Phase III POLO study for LYNPARZA was progression-free survival (PFS) assessed by blinded independent central review (BICR), with overall survival (OS) and overall response rate (ORR) as additional efficacy endpoints.
• The primary efficacy measures for the Phase III study of VITRAKVI were objective response rate (ORR) and duration of response (DoR), as evaluated by a blinded independent review committee (BIRC) using RECIST v1.1 criteria.
• On December 2024, Merus N.V. announced that the FDA approved BIZENGRI® (zenocutuzumab-zbco), the first and only treatment for adults with advanced unresectable or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion, who have experienced disease progression after prior systemic therapy.
• In December 2024, the FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri), the first systemic therapy for NSCLC or pancreatic adenocarcinoma (PDAC) with an NRG1 gene fusion.

Download the Sample PDF to Get More Insight @ Pancreatic Adenocarcinoma Market Forecast

DelveInsight's "Pancreatic Adenocarcinoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Pancreatic Adenocarcinoma, historical and forecasted epidemiology as well as the Pancreatic Adenocarcinoma therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pancreatic Adenocarcinoma market report provides current treatment practices, emerging drugs, Pancreatic Adenocarcinoma market share of the individual therapies, current and forecasted Pancreatic Adenocarcinoma market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current Pancreatic Adenocarcinoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Pancreatic Adenocarcinoma market.

Pancreatic Adenocarcinoma Treatment Market

The DelveInsight’s Pancreatic Adenocarcinoma market report gives a thorough understanding of the Pancreatic Adenocarcinoma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Pancreatic Adenocarcinoma Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Pancreatic Adenocarcinoma.

Pancreatic Adenocarcinoma Treatment

It covers the details of conventional and current medical therapies available in the Pancreatic Adenocarcinoma market for the treatment of the condition. It also provides Pancreatic Adenocarcinoma treatment algorithms and guidelines in the United States, Europe, and Japan. Pancreatic adenocarcinoma clinical trials are exploring novel therapies, including immunotherapies, targeted agents, and combination regimens, aiming to improve survival outcomes and address high unmet needs in this aggressive cancer.

Pancreatic Adenocarcinoma Epidemiology 

The Pancreatic Adenocarcinoma epidemiology section provides insights about the historical and current Pancreatic Adenocarcinoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Pancreatic Adenocarcinoma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Pancreatic Adenocarcinoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

• As per SEER (2024), it is estimated that there will be 66,440 new cases of pancreatic cancer in 2024.
  Among the molecular alterations, KRAS2 mutation is most common type of mutation observed in pancreatic cancer, followed by TP53, and p16/CDKN2A.
• As per DelveInsight estimates, exocrine pancreatic cancer is more common than the neuroendocrine pancreatic cancer accounting for more than 90% of total cases. The most common type of pancreatic cancer is adenocarcinoma. About 9 out of 10 people with pancreatic cancer have this type of cancer.
• In 2023, among the treated pancreatic patients, majority patients experienced disease progression from the first-line to the second-line treatment.

Country Wise- Pancreatic Adenocarcinoma Epidemiology

The epidemiology segment also provides the Pancreatic Adenocarcinoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

Pancreatic Adenocarcinoma Drug Chapters

The drug chapter segment of the Pancreatic Adenocarcinoma report encloses the detailed analysis of Pancreatic Adenocarcinoma marketed drugs and late-stage (Phase-III and Phase-II) Pancreatic Adenocarcinoma pipeline drugs. It also helps to understand the Pancreatic Adenocarcinoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The Pancreatic Adenocarcinoma drugs market is witnessing significant growth due to rising incidence, ongoing clinical trials, and promising targeted therapies, offering new hope for improved patient outcomes and survival.

Pancreatic Adenocarcinoma Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for Pancreatic Adenocarcinoma treatment.

Pancreatic Adenocarcinoma Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Pancreatic Adenocarcinoma treatment.

Pancreatic Adenocarcinoma Market Outlook

The Pancreatic Adenocarcinoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Pancreatic Adenocarcinoma market trends by analyzing the impact of current Pancreatic Adenocarcinoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Pancreatic Adenocarcinoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pancreatic Adenocarcinoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Pancreatic Adenocarcinoma market in 7MM is expected to witness a major change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Pancreatic Adenocarcinoma market in 7MM.

The United States Pancreatic Adenocarcinoma Market Outlook

This section provides the total Pancreatic Adenocarcinoma market size and market size by therapies in the United States.

EU-5 Countries Pancreatic Adenocarcinoma Market Outlook

The total Pancreatic Adenocarcinoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Pancreatic Adenocarcinoma Market Outlook

The total Pancreatic Adenocarcinoma market size and market size by therapies in Japan is also mentioned.

Pancreatic Adenocarcinoma Recent Developments

• On December 2024, Merus N.V. announced that the FDA approved BIZENGRI® (zenocutuzumab-zbco), the first and only treatment for adults with advanced unresectable or metastatic pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion, who have experienced disease progression after prior systemic therapy.
• In December 2024, the FDA granted accelerated approval to zenocutuzumab-zbco (Bizengri), the first systemic therapy for NSCLC or pancreatic adenocarcinoma (PDAC) with an NRG1 gene fusion.

Pancreatic Adenocarcinoma Drugs Uptake

This section focuses on the rate of uptake of the potential Pancreatic Adenocarcinoma drugs recently launched in the Pancreatic Adenocarcinoma market or expected to get launched in the market during the study period 2020-2034. The analysis covers Pancreatic Adenocarcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Pancreatic Adenocarcinoma Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Pancreatic Adenocarcinoma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Pancreatic Adenocarcinoma Pipeline Development Activities

The Pancreatic Adenocarcinoma pipeline report provides insights into different Pancreatic Adenocarcinoma clinical trials within Phase II, and Phase III stage. It also analyses Pancreatic Adenocarcinoma key players involved in developing targeted therapeutics.

Pancreatic Adenocarcinoma Pipeline Development Activities

The Pancreatic Adenocarcinoma clinical trials analysis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Pancreatic Adenocarcinoma emerging therapies. 

Reimbursement Scenario in Pancreatic Adenocarcinoma

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Pancreatic Adenocarcinoma market trends, we take KOLs and SMEs ' opinion working in the Pancreatic Adenocarcinoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Pancreatic Adenocarcinoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Pancreatic Adenocarcinoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Pancreatic Adenocarcinoma Market Report

• The report covers the descriptive overview of Pancreatic Adenocarcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Pancreatic Adenocarcinoma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Pancreatic Adenocarcinoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Pancreatic Adenocarcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pancreatic Adenocarcinoma market

Pancreatic Adenocarcinoma Market Report Highlights

• In the coming years, the Pancreatic Adenocarcinoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The Pancreatic Adenocarcinoma companies and academics are working to assess challenges and seek opportunities that could influence Pancreatic Adenocarcinoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Pancreatic Adenocarcinoma. The launch of emerging therapies will significantly impact the Pancreatic Adenocarcinoma market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Pancreatic Adenocarcinoma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Pancreatic Adenocarcinoma Market Report Insights

• Pancreatic Adenocarcinoma Patient Population
• Pancreatic Adenocarcinoma Therapeutic Approaches
• Pancreatic Adenocarcinoma Pipeline Analysis
• Pancreatic Adenocarcinoma Market Size and Trends
• Pancreatic Adenocarcinoma Market Opportunities
• Impact of upcoming Pancreatic Adenocarcinoma Therapies

Pancreatic Adenocarcinoma Market Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Pancreatic Adenocarcinoma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Pancreatic Adenocarcinoma Drugs Uptake

Pancreatic Adenocarcinoma Market Report Assessment

• Current Pancreatic Adenocarcinoma Treatment Practices
• Pancreatic Adenocarcinoma Unmet Needs
• Pancreatic Adenocarcinoma Pipeline Product Profiles
• Pancreatic Adenocarcinoma Market Attractiveness
• Pancreatic Adenocarcinoma Market Drivers
• Pancreatic Adenocarcinoma Market Barriers

Key Questions Answered In The Pancreatic Adenocarcinoma Market Report:

Pancreatic Adenocarcinoma Market Insights:

• What was the Pancreatic Adenocarcinoma drug class share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Pancreatic Adenocarcinoma total market size as well as market size by therapies across the 7MM during the forecast period (2020-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Pancreatic Adenocarcinoma market size during the forecast period (2020-2034)?
• At what CAGR, the Pancreatic Adenocarcinoma market is expected to grow by 7MM during the forecast period (2020-2034)?
• What would be the Pancreatic Adenocarcinoma market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Pancreatic Adenocarcinoma market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Pancreatic Adenocarcinoma Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the Pancreatic Adenocarcinoma?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Pancreatic Adenocarcinoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Pancreatic Adenocarcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Pancreatic Adenocarcinoma?
• Out of all 7MM countries, which country would have the highest prevalent population of Pancreatic Adenocarcinoma during the forecast period (2020-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Pancreatic Adenocarcinoma Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Pancreatic Adenocarcinoma treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Pancreatic Adenocarcinoma in the USA, Europe, and Japan?
• What are the Pancreatic Adenocarcinoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many Pancreatic Adenocarcinoma companies are developing therapies for the treatment of Pancreatic Adenocarcinoma?
• How many therapies are in-development by each company for Pancreatic Adenocarcinoma treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Pancreatic Adenocarcinoma treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Adenocarcinoma therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pancreatic Adenocarcinoma and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Pancreatic Adenocarcinoma?
• What are the global historical and forecasted market of Pancreatic Adenocarcinoma?

Reasons to buy Pancreatic Adenocarcinoma Market Forecast Report

• The report will help in developing business strategies by understanding trends shaping and driving the Pancreatic Adenocarcinoma market
• To understand the future market competition in the Pancreatic Adenocarcinoma market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Pancreatic Adenocarcinoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Pancreatic Adenocarcinoma market
• To understand the future market competition in the Pancreatic Adenocarcinoma market